Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Devicor Medical Products gets $250 million for acquisitions: Start-up seeks device acquisition to serve as a platform for growth, supported by a commitment for up to $250 million in financing from private equity firm and partner GTCR Golder Rauner. Announced March 10, the start-up is headed by CEO Thomas Daulton, former Cardinal Health general manager of Interventional Specialties and MedSystems divisions. Pleasant Prairie, Wis.-based Devicor Medical Products is seeking to buy "established interventional medical device businesses that manufacture and sell products to clinicians in settings such as hospitals, surgery centers or ambulatory clinics," the firm states. Devicor expects to complete an initial purchase in the $150 million-$400 million price range this year, supported in part with debt financing; smaller deals likely would follow, according to the company

You may also be interested in...



J&J/Ethicon Endo-Surgery Weighs Breast Care Divestiture To Devicor

Devicor Medical Products is seeking a foothold in the device market with its proposed acquisition of Johnson & Johnson/Ethicon Endo-Surgery's breast care business, the company announced March 30

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel